Skip to main content

Opaxio

Generic name: paclitaxel poliglumex
Treatment for: Non Small Cell Lung Cancer, Ovarian Cancer, Glioblastoma Multiforme, Head and Neck Cancer

Opaxio Combined with Alimta Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer

Encouraging progression-free survival in investigator sponsored trial results published at 13th World Conference on Lung Cancer

 

 

 

SEATTLE, August 03, 2009 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) announced results from a study released by Dartmouth-Hitchcock Medical Center at the International Association for the Study of Lung Cancer (IASLC) 13th World Conference on Lung Cancer. The study demonstrated that in patients with advanced non-small cell lung cancer (NSCLC), the combination of OPAXIO (paclitaxel poliglumex) and Alimta(R) (pemetrexed) was well tolerated and resulted in median progression-free survival of 3.3 months.

 

The study, led by Dr. J. R. Rigas, enrolled twelve patients, six to each of two dose levels. Patients were treated in 21-day cycles, with cohort one receiving 135 mg/m2 of paclitaxel poliglumex and 500 mg/m2 of pemetrexed, and cohort two receiving 175 mg/m2 of paclitaxel poliglumex and 500 mg/m2 of pemetrexed. None of the patients in cohort one had an initial dose-limiting toxicity (IDLT) with two cycles of therapy. There was one IDLT of infection with neutropenia in cohort two. Aside from grade 3 fatigue in two patients, there were no grade 3 or greater nonhematologic toxicities. A median of 4.5 cycles was delivered in each cohort.

 

The best response was stable disease in nine patients. Two patients remain without evidence of disease progression, and six patients were alive at time of data presentation. Median progression free survival was 3.3 months.

OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that OPAXIO metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit .

 

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: deramian@ctiseattle.com
    
    Investors Contact:
    Ed Bell
    T: 206.282.7100
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    
    Medical Information Contact:
    T: 800.715.0944
    E: info@askarm.com

 

 

 

 

SOURCE Cell Therapeutics, Inc.

CONTACT: Media, Dan Eramian, +1-206-272-4343, Cell, +1-206-854-1200,, Investors, Ed Bell, +1-206-282-7100, Lindsey JeschLogan, +1-206-272-4347, fax, +1-206-272-4434, , all ofCell Therapeutics, Inc., Medical Information, +1-800-715-0944, deramian@ctiseattle.com invest@ctiseattle.com info@askarm.com

Ticker Symbol: (NASDAQ-NMS:CTIC)

Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: August 2009

Related articles

Opaxio (paclitaxel poliglumex) FDA Approval History

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.